Drug Testing: How TARA Biosystems and BioIVT are Overcoming Scaling Challenges in Organ-On-a-Chip Technology
Which Application Segment Will Drive the Highest Demand in the Organ-On-a-Chip Market in 2024?
In 2024, the Drug Discovery and Toxicology Research segments are projected to lead the Organ-On-a-Chip (OoC) market.
Drug discovery, in particular, is expected to see significant demand as pharmaceutical companies increasingly adopt OoC platforms to simulate human organ responses in a controlled, scalable manner.
The global emphasis on precision medicine and the need for faster, more cost-effective drug development processes are driving the popularity of these applications.
Additionally, toxicology research, which traditionally relied on animal testing, is undergoing a transformation as organ-on-a-chip technology offers a more accurate and ethical alternative for toxicity testing and safety assessment.
Top innovators like Emulate, Inc. and CN Bio Innovations Limited are pioneering advances in drug development applications with organ-on-a-chip devices that can model liver, kidney, and lung responses.
Emulate’s Human Emulation System, for example, provides a human-relevant platform that enables drug developers to assess drug behavior and toxicity in human organs.
TissUse GmbH from Germany is also making strides with multi-organ systems designed to replicate various human organ interactions, further supporting drug efficacy and safety insights during early-stage testing.
How Does Organ-On-a-Chip Technology Impact Cost-Effectiveness and Accuracy in Drug Discovery and Toxicology?
Organ-on-a-chip technology has shown remarkable potential in reducing the time and cost associated with traditional drug discovery and toxicology testing.
By mimicking human organ structures and functions, OoC platforms eliminate the need for preliminary animal testing and enhance the accuracy of drug responses, leading to faster drug approval timelines and lower R&D expenditures.
For instance, InSphero in Switzerland has created 3D InSight™ Human Liver and Heart Microtissues, enabling pharmaceutical companies to conduct long-term toxicity studies with precision.
These human-based models not only offer high predictability for human responses but also reduce reliance on animal models, thereby lowering costs and streamlining the testing process.
In toxicology, companies like Hµrel Corporation have developed liver-based OoC models capable of predicting drug-induced liver injury (DILI), which is crucial for determining safe dosage levels and mitigating adverse effects early in the drug development process.
What Are the Key Challenges in Scaling Organ-On-a-Chip Technology for Drug Discovery and Toxicology Applications?
Despite the clear advantages of OoC technology, challenges remain, particularly in terms of scalability, regulatory compliance, and data validation.
One major hurdle lies in the complexity of scaling up OoC devices for industrial use. The process of replicating complex human organ systems on microchips is highly technical and demands precision, making mass production challenging.
Regulatory acceptance is another significant challenge, as OoC technology must be rigorously validated to meet international standards.
BioIVT and HemoShear Therapeutics are addressing these barriers by working closely with regulatory bodies to standardize the validation of their platforms, helping to ensure that OoC models meet safety and efficacy standards globally.
Additionally, MIMETAS BV in the Netherlands has introduced OrganoPlate®, a scalable platform compatible with automated workflows, helping to overcome production challenges and make these devices more accessible to researchers in the pharmaceutical and biotech industries.
Which Companies Are Leading Innovations in Organ-On-a-Chip Applications for Drug Discovery and Toxicology?
Several companies are at the forefront of innovation in the Organ-On-a-Chip market, each bringing unique technologies and advancements to the field.
Emulate, Inc. is recognized for its proprietary Organ-Chip technology, which simulates the microenvironment of human organs. Emulate’s chips, such as their Liver-Chip and Brain-Chip, provide high fidelity data on drug metabolism and blood-brain barrier interactions, respectively, revolutionizing drug discovery protocols.
Nortis, Inc. is another leader in the OoC space, offering vascularized organ models that enhance the understanding of how drugs interact with blood vessels and tissues.
Their vascularized chips are particularly useful for anti-cancer drug testing and precision medicine applications.
Axosim in the United States focuses on nerve-on-a-chip technology, allowing researchers to study neurotoxicity and peripheral nerve interactions, offering invaluable insights for neuropharmacology and toxicity research.
In addition to these companies, TARA Biosystems specializes in heart-on-a-chip models, which provide critical information for cardiotoxicity screening.
Their models are increasingly used by pharmaceutical companies to identify potential cardiac side effects before clinical trials, thereby enhancing drug safety profiles and expediting the development process.
For more information visit at MarketResearchFuture
Other Trending Reports
English